Overview

IMGN901 in Combination With Lenalidomide and Dexamethasone

Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test IMGN901 in combination with lenalidomide and dexamethasone every 28 days.
Phase:
Phase 1
Details
Lead Sponsor:
ImmunoGen, Inc.
Treatments:
Ado-Trastuzumab Emtansine
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Lenalidomide
Lorvotuzumab mertansine